Despite marked sensitivity to both chemotherapy and radiotherapy the overwhelming majority of small cell (oat cell) carcinomas of the bronchus are incurable. Whilst initial treatment results in substantial reduction in the tumour for most patients, subsequent recurrence with resistance to salvage therapy is the rule. In a recent analysis (Souhami & Law, 1990) less than 6% of patients were found to have survived 2 years from diagnosis.
The high metabolic rate and neuroectodermal ontogeny of small cell lung cancers result in the production of a variety of substances with potential for use as tumour markers. Enzymes (Carney et al., 1982; Bork et al., 1988) , secretory peptides Sobol et al., 1986; North et al., 1988) , hormones (Hansen et al., 1980) and cell surface molecules (Sculier et al., 1985; Jaques et al., 1988) have all been assayed in the circulation in the hope of identifying those which might contribute to the management of patients, either by screening for early diagnosis, defining prognosis or guiding treatment. To date however none has proven overwhelmingly superior and the need remains to examine potential candidates for their applicability in a variety of patient groups. This report details the results of an analysis of neurone specific enolase (NSE) 
Treatment
The majority of patients (119) received initial treatment with etoposide given as a single agent in a series of phase II and phase III studies designed to investigate the optimal dose schedule for this drug (Slevin et al., 1989 
Exclusions
During the period of the study, 55 patients commenced chemotherapy for whom no samples were stored, either for logistic reasons or because they declined phlebotomy. In patients for whom no pre-treatment sample was available but for whom sequential samples had been stored these latter were analysed during remission and relapse.
Tumour marker assays
Serum aliquots for measurement of NSE, LDH, ChrA and CEA levels were thawed within 4 h before the assays were performed. NSE was measured in serum using a radioimmunoassay (Pharmacia Diagnostics AB, Uppsala). The normal range is 0-12.5mgl l with a lower detection limit of 2.0 mgl1'. LDH was measured using a kinetic enzyme assay (Merck, Darmstadt) . The normal range is 80-240iul-'. CEA was measured by immunoradiometric assay (Medgenix Diagnostics, Brussels) . The normal range is 0-3.0mg 1' with a lower detection limit of 0.14mgl1'. ChrA was measured by double antibody competitive radioimmunoassay at the Nichols Institute, San Juan Capistrano, California.
The normal range is 0-50 mg 1' with a lower detection limit of 1.5mgl"'.
Statistical methods
Survival curves were calculated by the method of Kaplan and Meier, and the log-rank method used to test differences between them (Kaplan & Meier, 1958) . Multivariate analysis was carried out using Cox regression (Cox, 1972) . The natural logarithms of variables with non-normal distributions were used in regression analysis to reduce the influence of widely outlying values. The Mann-Whitney test was used to compare marker levels in different groups of patients and the prevalence of elevated levels in different groups was compared by contingency tables and calculation of x2 with Yates' correction. A level of P < 0.05 was taken as significant.
Results
The objective response rate to chemotherapy was 67% with 13 (8%) complete responses and 91 (59%) partial responses. 'ritne (yi3sr,s) Too few clinical complete responses were seen to allow separate analysis of marker levels in remission for those reaching complete as opposed to partial response. There was however a highly significant association between the NSE level at the time of remission and the duration of the remission (P<0.0001). Similarly a fall of 50% or more in the NSE level with treatment also correlated with increased remission duration (P<0.05), as did a fall of 50% or more in LDH (P <0.01). Changes in ChrA and CEA levels showed no significant relationship with duration of remission.
In analysing serial measurements of marker levels it was evident that in some patients the levels initially fell during treatment but subsequently rose again despite continued chemotherapy. That this might be due to outgrowth of a chemoresistant tumour sub-clone was tested by analysing the time to disease progression after the end of chemotherapy. Patients with such rising NSE, LDH or ChrA levels during chemotherapy had a shorter duration of remission than those with steady or falling levels, an association which reached significance in the case of NSE where the median remission durations of the two groups were 4 and 7 months respectively (Figure 4) . Changes in marker levels at the time of recurrence Analysis of marker levels between the time of clinical response and disease progression showed that ChrA levels rose prior to clinically-detectable relapse in 16 of 31 (52%) patients. LDH levels rose in 17 of 42 (40%), NSE levels in 17 of 45 (38%) and CEA levels in 12 of 33 (37%). (Table IV) . Two patients had rises in the levels of each marker without subsequently developing clinical evidence of recurrence during follow up. The treatment of small cell lung cancer remains frustrating in that very few long-term cures are achieved despite evident sensitivity to both chemotherapy and radiotherapy. The possibility of increasing the cure rate by selecting those patients for whom an intensification of treatment may be worthwhile is an appealing prospect for a reliable prognostic system. Conversely the identification of the much larger group of patients for whom cure is impossible is equally important if unjustifiable toxicity is to be avoided in their palliative treatment. Whilst the clinical staging system used for small cell lung cancer certainly has prognostic significance it may be that this can be refined by the use of tumour markers. A further potential application of tumour markers is in the subsequent management of patients receiving treatment: the extension of therapy for those nearly, but not quite, cured might be possible were a serological test for the presence of residual disease available, and an early indicator for imminent relapse would allow prompt 'salvage' treatment to be started. The present study attempts to define areas where progress may be made in addressing these issues. The population of patients studied necessarily represents a selected sample of those developing small cell lung cancer. Referral to a specialist centre with a particular interest in the illness is one means by which this selection has occurred, and the restriction to those patients well enough to consent to have samples stored is another. Although the patients within the study thus represent a group with relatively good prognosis, it is encouraging that the results of the univariate analyses of other prognostic factors are the same whether or not those patients excluded from the multivariate analysis are included. This suggests that the multivariate analysis from the smaller sample may nonetheless be more widely applicable.
This study has confirmed the previous findings of elevated NSE levels in the majority of patients with small cell lung cancer, although in a rather higher proportion than previously reported, particularly in those with limited disease (Esscher et al., 1985; Bork et al., 1988; Jorgensen et al., 1989) . That 81% of patients have elevated levels at presentation suggests that this may be a useful diagnostic test where the histological or cytological features are in doubt, since less than one fifth of patients with non-small cell lung cancer have raised levels (Burghuber et al., 1990) . Neurone-specific enolase levels are higher in patients with extensive disease but there is considerable overlap with limited disease. That NSE does not relate solely to anatomic tumour burden is also suggested by the finding that the levels initially fell regardless of the response to chemotherapy. The additional finding of a shorter remission duration in patients whose levels subsequently rose again despite continued treatment may have considerable significance for the selection of therapy and should be prospectively tested in larger numbers of patients. The prognostic significance of NSE level has only been tested in multivariate analysis in one previous study (Jorgensen et al., 1988) , whose results are confirmed here. Neurone-specific enolase is the best single predictor of both remission duration and overall survival in this series of patients and although closely correlated with the more widely used LDH it carries independent power even when the latter is included in regression analysis. This is of particular relevance in patients with a relatively good prognosis: of 34 patients with NSE below twice normal and performance status 80 or more only one had a raised LDH, whilst of 52 patients with normal LDH and performance status of 80 or more 19 had NSE above twice normal and formed a group with significantly worse survival (P = 0.012). The neuronespecific enolase thus contributes additional information in approximately one third of such patients.
Chromogranin A has particular relevance to the detection of treatment failure, for which it appears superior to the other markers examined. The majority of patients for whom initial chemotherapy failed showed rising ChrA levels during treatment and 78% of patients had rises at the time of recurrence. Just over half these pre-dated the clinical diagnosis by a median interval of 10 weeks. Although there is a correlation between ChrA and LDH levels at presentation and both are predictive of the response rate to chemotherapy, the association is lost during treatment as LDH levels fall in nearly all patients irrespective of the response.
Several previous studies have examined the usefulness of CEA as a marker for small cell lung cancer, but as in this case the proportion of patients with elevated levels at presentation has generally been reported as less than half (Goslin et al., 1981; Lokich, 1982; Sculier et al., 1985) , limiting its applicability. The use of CEA as a prognostic factor has yielded inconclusive results with some studies reporting a relationship between presentation level and survival (Sculier et al., 1985; Laberge et al., 1987; Krischke et al., 1988) , although multivariate analyses were not performed and others found no correlation (Lokich, 1982; Waalkes et al., 1982; Jaques et at., 1988) , a result confirmed in this study. Studies of serial measurements of CEA have suggested that these correlate closely with the clinical course (Woo et al., 1981; Havemann et al., 1985; Shinkai et al., 1986 ) although this was not the finding in this study.
Conclusion
This study has confirmed the utility of NSE as a sensitive marker for small cell lung cancer and demonstrated its preeminent prognostic significance in multivariate analysis for remission duration and survival. A rising level of NSE during treatment following an initial fall is predictive of short remission duration, suggestive of the emergence of resistance, and future studies to investigate this further may broaden its usefulness for directing changes of therapy. LDH has also been shown to be of prognostic significance although closely related to NSE, to which it is generally inferior. A raised LDH does however appear to predict the likelihood of chemoresistance to some extent, as does raised ChrA. The sensitivity of ChrA to treatment failure suggests that it may be of considerable use in monitoring remission, and prospective studies are now needed to define its predictive power. This might allow testing of the hypothesis that early salvage chemotherapy for recurrent disease could improve the outlook for what is at present a very poor situation. In summary the combination of NSE as a prognostic factor and monitor during active treatment and ChrA during remission to detect early recurrence would appear the ideal at present, although clearly the development of more effective agents for treatment is a goal to render such considerations redundant. Without such agents, however, the use of markers may enable the more rational and effective use of those that are available.
